NCT04124510 (SWIFT) is a Phase 3 clinical trial of Brand Name: Flutiform K-haler in Asthma, sponsored by Mundipharma Korea Ltd.

Who is sponsoring NCT04124510?

NCT04124510 is sponsored by Mundipharma Korea Ltd.

What drugs are being tested in NCT04124510?

Interventions in NCT04124510: Brand Name: Flutiform K-haler.

Is NCT04124510 still recruiting?

NCT04124510 is currently terminated. Last updated 25 January 2021.

Last reviewed 2021-01-25 · How we verify

NCT04124510: SWIFT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy

Terminated Phase 3 Last updated 25 January 2021

What this trial tests

Phase 3 trial testing Brand Name: Flutiform K-haler in Asthma in 20 participants. Terminated before completion.

Timeline

26 November 2019

Primary endpoint
14 September 2020

14 September 2020

Quick facts

Lead sponsor	Mundipharma Korea Ltd
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	26 November 2019
Primary completion	14 September 2020
Estimated completion	14 September 2020
Sites	1 location across South Korea

Drugs / interventions tested

Brand Name: Flutiform K-haler — full drug profile →

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

Mundipharma Korea Ltd — full company profile →

Who can join

19 and older, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy of the Asthma improvement of Flutiform K-haler after 12 weeks of treatment in patients with moderate to severe uncontrolled\* asthma following mid-dose ICS/LABA DPI therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Mundipharma Korea Ltd trials

Trials by the same sponsor.

NCT03768466 — Efficacy and Safety of Oxycodone/Naloxone (Targin®) in Persistent Moderate to Severe Low Back Pain Following NSAIDs Trea · Phase 4 · completed
NCT02732886 — Betafoam Diabetes Mellitus Foot Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04124510 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mundipharma Korea Ltd
Last refreshed: 25 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04124510.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing